MOHAP to EDE: What Changed for UAE Pharmaceutical Establishments in 2026

V-Sentinel Editorial · Healthcare supply chain compliance, GCC

---

If the last regulatory letter you received still bore the MOHAP letterhead, your file has moved. On 29 December 2025, the Ministry of Health and Prevention formalised the transfer of forty-four pharmaceutical services to the Emirates Drug Establishment, a federal authority created in late 2023 that has progressively assumed operational responsibility over the two years since.¹ For wholesalers, 3PLs, importers and hospital pharmacies, this is not a rebrand. It is a structural change to who issues your licence, who inspects your warehouse, and where every application now lives.

This article is for compliance leads and quality managers who need a practical view of what changed, what stayed, and what to do about it before the next inspection cycle.

Who the EDE is, and what it now controls

The Emirates Drug Establishment was established on 29 September 2023 as the UAE's federal authority responsible for regulating pharmaceutical and medical products.² From late 2025 onward, the EDE assumed responsibility for the services previously delivered by MOHAP's Drug Department: marketing authorisations, import and export permits, GMP certification, pharmaceutical facility licensing (factories, warehouses, medical stores, scientific offices), and pharmacovigilance oversight. Healthcare facility licensing at emirate level — DHA in Dubai, DOH in Abu Dhabi — sits alongside this federal remit rather than inside it.

In practical terms, three things shifted at once. First, the portal. All applications, renewals and submissions for the transferred services now go through ede.gov.ae rather than MOHAP's drug services pages. Second, the inspectorate. EDE inspection teams now conduct the warehouse and facility visits that MOHAP teams used to run, with an increasingly risk-based inspection approach and findings recorded into a central digital system. Third, the cadence. The EDE has reported more than 568 inspection visits at medical warehouses across the country in the first months of 2026 alone — a meaningful step up in frequency.³

What did not change is the underlying technical standard. The UAE's Good Storage & Distribution Practice document, issued under MOHAP, remains the working reference for storage conditions, transport, recall procedures and documentation.⁴ The technical standard is largely the same. The inspecting authority has changed.

What is genuinely different in practice

For most distributors, the change appears first as friction. A renewal that used to live in one MOHAP folder is now split across two regulators if any non-pharmaceutical scope sits inside the licence. A vendor master that referenced "MOHAP-approved" against each line item is now technically incorrect. SOPs that name MOHAP as the inspecting authority will be flagged on first inspection if not updated.

Beyond the housekeeping, three substantive shifts deserve attention.

The first is traceability enforcement. Tatmeen, the UAE's GS1-aligned serialisation platform, went live in December 2022, and enforcement has tightened in step with the EDE's expanded remit.⁵ Tatmeen commissioning is a core requirement for the importation and distribution of covered medicinal products in the UAE, and EDE inspection activity increasingly includes verification of scan compliance and aggregation hierarchy against the platform — a level of digital cross-checking that materially raises the cost of weak serialisation governance. Beyond compliance, Tatmeen data holds significant untapped intelligence value for distributors willing to use it.

The second is inspection style. EDE inspectors arrive with two reference frames at once: the long-standing MOHAP storage guidance, and a greater emphasis on documented risk management across the activities of the establishment. The implication for distributors is that the inspection is less a checklist walkthrough and more a documented assessment of how risk is being managed across temperature controls, transport, deviation handling and supplier qualification. The eight domains typically reviewed during an EDE visit are covered in detail in our GDP inspection readiness guide.

The third is non-compliance consequences. The EDE has enforcement powers to inspect without prior notice, seize non-compliant products, suspend or revoke marketing authorisations, and shut down establishments that violate the law. These powers existed in some form before, but they now sit with a single federal authority with a clearer mandate and a digital evidence trail. Regulatory tolerance for unresolved CAPAs appears materially lower under the consolidated framework.

What to do this quarter

For an established UAE distributor, the practical work falls into four areas, all of which can be completed inside a quarter without external help if internal QA capacity is available.

Update every SOP, work instruction and quality manual that names MOHAP as the inspecting authority, the issuer of the licence, or the receiver of regulatory notifications. The change should be tracked as a controlled document revision, not a global find-and-replace, because the underlying responsibilities sometimes shift along with the name. Where a procedure references the MOHAP Drug Department, confirm whether the function moved to the EDE or remained inside MOHAP, and reflect the correct authority.

Reconcile your licence file. If your last EDE or MOHAP correspondence sits in a personal inbox, move it into the controlled record. Confirm the current expiry date, the responsible person of record, and the scope of activities on the licence as held by the EDE. Where any field is out of date, raise the correction through the EDE portal before the next inspection rather than during it.

Audit your Tatmeen position. Run a sample reconciliation of inbound product against commissioning events for the past sixty days. Aggregation errors, missing parent-child links, and unscanned returns are the three findings most likely to surface during a digital cross-check.

Brief the floor. Inspections happen to warehouse teams, not to head office. A thirty-minute toolbox session covering who the EDE is, what they ask for on arrival, and where the inspection-day documents live is the lowest-cost intervention with the highest behavioural return.

---

V-Sentinel works with UAE wholesalers, 3PLs and importers on GDP inspection readiness across the EDE transition. If you want a structured view of where your operation stands, start with our GDP Readiness Assessment. Senior expert review, AI-powered delivery.

---

Sources

Footnotes

1. Ministry of Health and Prevention (UAE), Announcement on the Transfer of Selected Services to the Emirates Drug Establishment, mohap.gov.ae. ↩

2. Emirates Drug Establishment, About EDE, ede.gov.ae. ↩

3. Emirates Drug Establishment, Inspection activity update, 2026 (as reported in Zawya and Gulf News coverage of the EDE announcement). ↩

4. Ministry of Health and Prevention (UAE), Good Storage and Distribution Practices Guidelines for Pharmaceutical Products, mohap.gov.ae. ↩

5. Ministry of Health and Prevention (UAE), Tatmeen — National Track and Trace Platform for Medicinal Products, mohap.gov.ae/tatmeen. ↩